A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

This study has been terminated.
(Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients resulting in poor data.)
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
First received: February 9, 2006
Last updated: April 9, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)